DermTech Surpasses 200,000 Cumulative Billable Samples for the DermTech Melanoma Test (DMT)
31 Maio 2023 - 9:00AM
Business Wire
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a
leader in precision dermatology enabled by a non-invasive skin
genomics platform, today announced that the DermTech Melanoma Test
(DMT) has tested more than 200,000 suspicious pigmented lesions.
The DMT uses non-invasive Smart Stickers™ to test for select
genomic markers associated with melanoma, one of the deadliest
forms of skin cancer. With a negative predictive value of over 99
percent, the test rules out melanoma with high probability.
“We are proud to have surpassed 200,000 cumulative billable
samples for the DMT,” said Bret Christensen, CEO, DermTech. “Our
test improves patient care and can potentially save lives. Our
dedicated team and healthcare provider partners were instrumental
in achieving this goal, as few medical technologies reach this
level of usage. Approximately one-third of U.S. dermatologists
ordered the DMT in 2022. We are building momentum and expect to
further integrate the DMT into the melanoma care pathway.”
“I am grateful to our exceptional lab team for their hard work
in helping us achieve this significant milestone,” said Claudia
Ibarra, chief operating officer, DermTech. “While we have already
made significant strides, our new, state-of-the-art facility in San
Diego is the foundation of our future growth. We are
well-positioned to further transform dermatology with our
non-invasive technology.”
“The DMT has entirely changed how I evaluate suspicious lesions
on my patients and enabled me to reduce the number of biopsies I
perform,” said Dr. Maral Kibarian Skelsey, director of the
Dermatologic Surgery Center of Washington. “This is critical
because so many of my patients are extremely hesitant to be cut.
With the DMT, I can reliably rule out melanoma in a non-invasive
manner, all while ensuring the highest quality of patient safety
and care.”
“I have had four melanomas throughout my life,” said Helen Fry,
a patient who has been tested with the DMT many times. “Before I
was introduced to the DMT, I knew that a trip to the dermatologist
meant that I would almost certainly be cut. Not only was this
anxiety-inducing, but it sometimes led me to postpone necessary
appointments. The DMT has changed my life for the better.”
This milestone announcement comes during Melanoma Awareness
Month, amidst DermTech’s third annual #Stickit2Melanoma campaign
aimed at raising awareness of melanoma and promoting the importance
of scheduling regular skin exams. For every #Stickit2Melanoma
pledge to schedule a skin exam made during May, DermTech will
donate $5 to its non-profit partner organizations. To find a
specialist to schedule a skin exam, visit
https://dermtech.com/pledge/.
About The DermTech Melanoma Test
DermTech originally marketed its foundational assay under the
name Pigmented Lesion Assay (PLA). The PLA assesses pigmented skin
lesions, moles or dark skin spots for melanoma. In particular, the
PLA detects expression of the LINC00518 (LINC) and preferentially
expressed antigen in melanoma (PRAME) genes using reverse
transcription-polymerase chain reaction (RT-PCR). The Company
introduced its second-generation test in 2021 as an add-on assay to
PLA, which is designed to identify the presence of mutations in
TERT gene promoter region using DNA sequencing. The Company has
since branded its PLA and TERT add-on-assay as the DermTech
Melanoma Test (DMT). The DMT may be ordered with or without the
add-on test for TERT. Positive results for LINC, PRAME or TERT
correlate with a lesion at higher risk for melanoma. If none of the
biomarkers are detected, this result indicates a greater than 99%
probability that the mole being tested is not melanoma.
About DermTech
DermTech is a leading genomics company in dermatology and is
creating a new category of medicine, precision dermatology, enabled
by its non-invasive skin genomics platform. DermTech’s mission is
to improve the lives of millions by providing non-invasive
precision dermatology solutions that enable individualized care.
DermTech provides genomic analysis of skin samples collected
non-invasively using our Smart Stickers™. DermTech markets and
develops products that facilitate the early detection of skin
cancers and is developing products that assess inflammatory
diseases and customize drug treatments. For additional information,
please visit DermTech.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of DermTech may differ from its actual
results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
"outlook," “anticipate,” “intend,” “plan,” “may,” “will,” “could,”
“should,” “believe,” “predict,” “potential,” “continue,” and
similar expressions are intended to identify such forward-looking
statements. These forward-looking statements include, without
limitation, expectations and evaluations with respect to: the
performance, patient benefits, cost- effectiveness,
commercialization and adoption of DermTech’s products and the
market opportunity for these products, DermTech’s positioning and
potential growth, financial outlook and future financial
performance, ability to monetize existing demand by increasing its
proportion of reimbursed billable samples, ability to maintain or
improve its operating efficiency and reduce operating expenses, the
sufficiency of DermTech’s cash resources and runway and ability to
access capital to fund its operating plan, implications and
interpretations of any study results, expectations regarding
agreements with or reimbursement or cash collection patterns from
Medicare, government payers or commercial payers and related
billing practices or number of covered lives and DermTech’s ability
to expand its product offerings and develop pipeline products.
These forward-looking statements involve significant risks and
uncertainties that could cause the actual results to differ
materially from the expected results. Most of these factors are
outside of the control of DermTech and are difficult to predict.
Factors that may cause such differences include, but are not
limited to: (1) the outcome of any legal proceedings that may be
instituted against DermTech; (2) DermTech’s ability to obtain
additional funding to develop and market its products; (3) the
existence of favorable or unfavorable clinical guidelines for
DermTech’s tests; (4) the reimbursement of DermTech’s tests by
Medicare, government payers and commercial payers; (5) the ability
of patients or healthcare providers to obtain coverage of or
sufficient reimbursement for DermTech’s products; (6) DermTech’s
ability to grow, manage growth and retain its key employees and
maintain or improve its operating efficiency and reduce operating
expenses; (7) changes in applicable laws or regulations; (8) the
market adoption and demand for DermTech’s products and services
together with the possibility that DermTech may be adversely
affected by other economic, business, and/or competitive factors;
and (9) other risks and uncertainties included in the “Risk
Factors” section of the most recent Annual Report on Form 10-K
filed by DermTech with the Securities and Exchange Commission (the
“SEC”), and other documents filed or to be filed by DermTech with
the SEC, including subsequently filed reports. DermTech cautions
that the foregoing list of factors is not exclusive. You should not
place undue reliance upon any forward- looking statements, which
speak only as of the date made. DermTech does not undertake or
accept any obligation or undertaking to release publicly any
updates or revisions to any forward-looking statements to reflect
any change in its expectations or any change in events, conditions,
or circumstances on which any such statement is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230531005243/en/
Steve Kunszabo DermTech (858) 291-1647
steve.kunszabo@dermtech.com
DermTech (NASDAQ:DMTK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
DermTech (NASDAQ:DMTK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024